Related references
Note: Only part of the references are listed.Specific Inhibition of Spleen Tyrosine Kinase Suppresses Leukocyte Immune Function and Inflammation in Animal Models of Rheumatoid Arthritis
Greg Coffey et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2011)
SYK regulates B-cell migration by phosphorylation of the F-actin interacting protein SWAP-70
Glen Pearce et al.
BLOOD (2011)
PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model
Michael P. Reilly et al.
BLOOD (2011)
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia
Mariela Sivina et al.
BLOOD (2011)
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brian J. Lannutti et al.
BLOOD (2011)
Critical role for Syk in responses to vascular injury
Patrick Andre et al.
BLOOD (2011)
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
Xavier C. Badoux et al.
BLOOD (2011)
SYK inhibition and response prediction in diffuse large B-cell lymphoma
Shuhua Cheng et al.
BLOOD (2011)
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
Julia Hoellenriegel et al.
BLOOD (2011)
Non-malignant B cells and chronic lymphocytic leukemia cells induce a pro-survival phenotype in CD14+ cells from peripheral blood
N. Bhattacharya et al.
LEUKEMIA (2011)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W. Friedberg et al.
BLOOD (2010)
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia
Maike Buchner et al.
BLOOD (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis.
Michael E. Weinblatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation
Jan A. Burger et al.
BLOOD (2009)
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406
Maite P. Quiroga et al.
BLOOD (2009)
Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia
Maike Buchner et al.
CANCER RESEARCH (2009)
Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells
S. Gobessi et al.
LEUKEMIA (2009)
The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCδ and proteasome-dependent regulation of Mcl-1 expression
A. D. Baudot et al.
ONCOGENE (2009)
CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment
Piers E. M. Patten et al.
BLOOD (2008)
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma
Linfeng Chen et al.
BLOOD (2008)
Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia
Andrea Buerkle et al.
BLOOD (2007)
R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation
Sylvia Braselmann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphomna
Jia Ruan et al.
CLINICAL CANCER RESEARCH (2006)
Signaling protein SWAP-70 is required for efficient B cell homing to lymphoid organs
Glen Pearce et al.
NATURE IMMUNOLOGY (2006)
Cutting edge: Constitutive B cell receptor signaling is critical for basal growth of B lymphoma
Murali Gururajan et al.
JOURNAL OF IMMUNOLOGY (2006)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells
BT Messmer et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Mechanisms of disease: Chronic lymphocytic leukemia
N Chiorazzi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Chronic lymphocytic leukemia: revelations from the B-cell receptor
FK Stevenson et al.
BLOOD (2004)
Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia
LG Chen et al.
BLOOD (2002)
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia
A Rosenwald et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Share Paper
